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Abstract
Background: This study was to investigate the effect of long term use of Renin-Angiotensin-Aldosterone System (RAAS) 
blocking agents on the Incidence of Contrast-Induced Nephropathy (CIN) on patients with Diabetes Mellitus (DM) and 
renal insufficiency underwent Percutaneous Coronary Intervention (PCI).
Methods: A total 281 of subjects were included in this study and divided into two groups based on prior use of RAAS 
blocking agents (RAAS +, n = 146; RAAS -, n = 135). CIN was defined as an increase of ≥25% in creatinin over baseline 
value 48-72 hours after PCI.
Results: Total incidence of CIN was 14,95%. There was no difference in the incidence of CIN between 2 study groups (p 
= 0,952) and relative risk for CIN was 1,02. Left Ventricular ejection Fraction (LVEF) ≤ 40 % (OR 2,300; 95% CI 1,028 
– 5,143; p = 0,043), anemia (OR 2,628; 95% CI 1,274 – 5,422; p = 0,009) and Glomerular Filtration rate (GFR) pre PCI 
≤ 60 mL/minute (OR 2,782; 95% CI 1,293 – 5,987; p = 0,009) were important predictors of CIN.
Conclusion: Long term use of RAAS blocking agents do not increase the incidence of CIN in patients with DM and renal 
insufficiency underwent PCI.
(Indonesian J Cardiol. 2019;40:195-201)
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Introduction
Contrast-Induced Nephropathy (CIN) is one of a serious complication of Percutaneous Coronary Intervention (PCI) whose incidence varies from 2% - 25% based on 
population and risk factors1,2. CIN is usually defined 
as an increase in serum creatinine by 25% or by 0,5 mg/
dL (44 mmol/L) from a baseline value by 48 – 72 hours 
post-contrast administration3. Renal insufficiency, 
diabetes mellitus (DM), congestive heart failure (CHF), 
doi: 10.30701/ijc.v40i1.920
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dehydration, elderly, anemia, and nephrotoxic drugs 
such as nonsteroidal anti-inflammatory drugs (NSAID) 
are known risk factors for CIN4. The development 
of CIN has been associated with increased length of 
hospitalization and 3x incidence of MACCE (Major 
Adverse  Cardiac and Cerebrovascular Events) at 1 year 
follow up ie: death, stroke, myocardial infarction (MI), 
and end-stage renal disease5.
 The role of the Renin-Angiotensin-Aldosterone 
System (RAAS) blocking agents in CIN is still 
controversial. Data from available literature are 
conflicting and discordant. Some study concluded 
that it was effective in the prevention of CIN2,6, but 
other studies concluded that it was a risk factor1,7–9. 
The reason behind these conflicting results is the 
pathomechanism of CIN that remain unclear. There 
is two main mechanisms leading to CIN, renal 
vasoconstriction induced medullary hypoxia, and direct 
toxicity of contrast media10. It has been speculated 
that RAAS blocking agents may decrease the vascular 
tone of efferent arteriole used to maintain glomerular 
hydrostatic pressure. The lower the hydrostatic pressure, 
the less glomerular filtration11,12. Experimental data 
suggest that increased endothelin-1, and reactive oxygen 
species are vital in the development of CIN, and can be 
inhibited using RAAS blocking agents13.
Methods
Study Population
An observational study with historical cohort design 
using medical records was performed in patients who 
were referred to National Cardiac Center “Harapan Kita” 
Hospital Jakarta for non-emergent PCI between January 
2012 and December 2013. Inclusion criteria were age > 
18 years old, diagnosed with DM and renal insufficiency 
(GFR 30-89 mL/min) at least 3 months prior to PCI, 
and Mehran score > 514. Patients were excluded if they 
had the following criteria: prior condition leading to 
renal hypoperfusion (i.e hypovolemia, systolic pressure 
< 90 mmHg, cardiogenic shock, cardiac arrest, sepsis, 
obstructive uropathy), administration of contrast load 
within 7 days, severe renal impairment (GFR < 30 mL/
min), subsequent surgery following PCI, nephrotoxic 
agent administration within 48 hours before the 
procedure  (NSAIDs, amphotericin B, aminoglycosides, 
cyclosporine), and severe anemia require blood 
transfusion. All patients received normal saline at rate 
1 mL/kg/h~maximum 100 mL/h for 6 h before and 6 
h after PCI. A total of 281 subjects met the inclusion 
criteria and divided into two groups: the RAAS (+) 
group (n = 146), who received any type of RAAS 
Tabel 1. Baseline characteristics
Characteristics RAAS + (146) RAAS – (135) p-value
Age, years 60,91 ± 8,27 58,71 ± 11,48 0,069
BMI 24,66 ±  3,47 24,59 ± 2,99 0,845
SBP 139,30 ± 26,84 137,73 ± 26,40 0,620
DBP 80,47 ± 18,18 83,51 ± 17,57 0,155
Hemoglobin 13,32 ± 1,77 13,70 ± 1,92 0,080
Cholesterol 169,86 ± 47,87 175,29 ± 48,03 0,344
LVEF 46,69 ± 16,66 43,67 ± 15,46 0,116
Duration of PCI 66,42 ± 25,57 60,82 ± 22,71 0,053
Contrast amount 165,19 ± 72,62 154,41 ±56,97 0,169
Mehran score 10,29 ± 3,64 9,49 ± 3,64 0,065
CHF 51 (34,9%) 44 (32,6%) 0,679
Female gender 28 (19,2%) 24 (17,8%) 0,763
NAC 37 (25,3%) 34 (25,2%) 0,976
Hypertension 27 (18,5%) 32 (23,7%) 0,284
Hypotension 3 (2,1%) 2 (1,5%) 0,537
Hypercholesterolemia 33 (22,6%) 39 (38,9%) 0,228
Anemia 55 (37,7%) 46 (34,1%) 0,530
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blocking agents at least 3 months before admission, and 
the RAAS (-) group (n = 135), who did not received any 
RAAS blocking agents before admission. 
Study Variables and Definitions
CIN was defined as an increase of ≥ 25% or ≥ 0,5 mg/dL 
(≥ 44mmol/L) in serum creatinine over the baseline value 
within 48 – 72 h of PCI3. DM was defined as a fasting 
plasma glucose ≥ 126 mg/dL, and or an oral glucose 
tolerance test ≥ 200 mg/dL, and or an AIC ≥ 6,5%, 
and or clinical diagnosis of diabetes with dietary, oral or 
insulin treatment15. GFR was calculated using Cockroft 
Gault: (140 – age) x weight (kg)/ serum creatinine (mg/
dL) x 72(x 0,8 in female). Patients with blood pressure 
≥ 140/90 mmHg were regarded as having hypertension. 
The presence of anemia was defined as a hemoglobin 
concentration < 12,0 g/dL in female or < 13,0 g/dL 
in male. Hypercholesterolemia was defined as having 
a total cholesterol concentration > 200 mg/dL. LVEF 
≤ 40% was examined using echocardiography before 
PCI. CHF was defined as NYHA III-IV criteria with 
LVEF ≤ 40%. Mehran score was calculated according to 
the assessment  of the associated risk factors, including 
volume of contrast media, baseline GFR, age, presence 
of hypotension, CHF, presence of anemia, and diabetes 
mellitus. A cutoff value of 60 mL/min – 89 mL/min and 
30 mL/min – 59 mL/min in GFR were used to define 
mild and moderate renal insufficiency, respectively3.
Statistical Analysis 
Continuous variables were given as mean ± standard 
deviation, and the comparisons of these variables were 
performed using student’s t-test.  Within-subjects 
comparisons of continuous variables i.e GFR and sCr 
were completed using the paired t-test. Categorical 
variables were analyzed using chi-square and were 
presented as absolute value and percentage. We 
performed bivariate analysis with CIN as dependent 
variables and potential risk factors as follow: age, 
BMI, LVEF, duration of PCI was performed, contrast 
amount, Mehran score,  variance of contrast media, 
use of RAAS blocking agent, hypertension, anemia, 
hypercholesterolemia, gender, CHF, use of NAC, GFR, 
and sCr. Variables that were statistically significant in 
bivariate analysis were included in the final multivariate 
model to identify predictors of CIN. P-value ≤ 0,05 was 
considered for statistical significance. A 2 x 2 table was 
used to calculate the relative risk of CIN. We performed 
statistical analysis using statistical analysis software. 
Results 
Two hundred and eighty-one (281) subject were 
included in the final analysis. Baseline characteristic is 
shown in table 1.
Markers of renal functions and incidence of 
CIN
Mean GFR before PCI was 50,85 mL/min with range 
30,05 – 89,27 mL/min. Mean sCr before PCI was 1,47 
md/dL with 0,7 mg/dL as minimum value and 3,0 mg/
dL as maximum value. Before PCI the two groups had 
comparable renal markers (table 2). After PCI, RAAS 
(-) groups had significantly higher GFR  compare to 
RAAS (+) (p = 0,026), as shown on absolute change (p 
= 0,007).
Table 2. Post PCI changes in renal parameters in two study groups
RAAS + RAAS - 95% CI p-value
GFR (mL/min)
Baseline 
Post PCI
Absolute change
49,85 ± 14,34a
51,28 ± 18,57a
1,43 ±13,71
51,92±14,46b
56,52 ± 20,78b
4,60 ± 19,50
-2,07 (-5,46 – 1,31)
-5,23 (-9,86 - 0,62)
-3,17 (-7,10 – 0,77)
0,229
0,026
0,114
sCr (mg/dL)
Baseline
Post PCI
Absolute change
1,49 ± 0,42c
1,52 ±0,58c
0,03 ± 0,47
1,45 ± 0,42d
1,45 ±0,66d
-0,003 ± 0,58
0,04 (-0,06 – 0,14)
0,07 (-0,08 – 0,22)
0,03 (-0,09 – 0,156)
0,429
0,345
0,626
Values are means ± SD
Student’s t test was used in statistical analysis between the groups and paired t-test in subject comparison. a p 0,210; b p 0,007; 
c p 0,471; d p 0,954
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 CIN occurred in 14,95% (42 of 281) of overall 
study population, 22 patients (15,07 %) on RAAS (+) 
group, and 20 patients (14,82%) on RAAS (-) group. 
There was no statistically significant difference in the 
incidence of CIN between two study groups (p 0,952). 
The relative risk of CIN based on chronic usage of RAAS 
blocking agents was 1,02.
Bivariate and Multivariate Analysis
On bivarate analysis, we studied 16 risk factors for the 
development of CIN. From the analysis, we found 
5 risk factors were associated with CIN were LVEF ≤ 
40 % (OR 2,421; 95% CI 1,233 – 4,751; p = 0,009), 
duration of PCI was performed  > 65 min(OR 2,021; 
95% CI 1,041 – 3,952; p = 0,035), anemia (OR 
1,988; 95% CI 1,025 – 3,852; p = 0,040), CHF (OR 
1,988; 95% CI 1,023 – 3,863; p = 0,040), and GFR 
pre PCI ≤ 60 mL/min (OR 2,683; CI 1,312 - 5,485; 
p = 0,005). Multivariate analysis showed that LVEF ≤ 
40 %, anemia, and GFR pre PCI ≤ 60 mL/min were 
important predictors of CIN (Table 3). 
Discussion
RAAS blocking agents usage and CIN
In this study, we found that there is no difference in CIN 
incidence in subjects with DM and renal insufficiency 
who were under chronic use of  RAAS blocking agents 
or not. This result was clinically important since 
previous studies gave inconsistent results1,6,8,9,16. CIN 
was one of the important complications after contrast 
administration for medical intervention and associated 
with an increased hospital stay and cost17.
 Mean Mehran score in this study was 9,52 ± 3,73. 
This meant that we had a chance to develop CIN as 
14%14. This exactly predicted a 14,95% CIN incidence 
in our total study population. Our finding was 
significantly lower than the previous study in the same 
center. On the previous study, the incidence of CIN 
was up to 25%. The reason probably was the difference 
between our study population, and prevention procedure 
that was a must in our study design18. Some study stated 
that prevention procedure decreases CIN significantly9
 One reason to explain these different results is the 
complex mechanism of CIN. Medullary hypoxia due to 
renal blood flow hypoperfusion secondary to arteriolar 
vasoconstriction dan direct toxicity of contrast media 
is widely known as the mechanism of CIN19. The 
imbalance between local vasoconstriction and local 
vasodilator also play a role in the development of CIN. 
Local vasoconstriction such as endothelin-1, renin, 
and angiotensin II compete with nitric oxide as a local 
vasodilator to maintain renal medullary perfusion. 
Increase the level of reactive oxygen species (ROS) and 
decrease the level of nitric oxide is also one mechanism 
leading to CIN12.
 In our study, both groups experienced an increase in 
GFR level after PCI as a result of a progressive preventive 
procedure. Meanwhile, GFR after PCI was significantly 
lower in RAAS (+) than on RAAS (-), probably due to a 
hypothesis that angiotensin II-mediated post glomerular 
efferent arteriolar vasoconstriction is important to 
maintain renal to perfusion pressure. Chronic inhibition 
on angiotensin II will decrease intraglomerular pressure 
thus decrease GFR20. RAAS blocking agents on 
physiologic condition does not appear to have toxic 
properties, but these agents will cause serious renal 
insufficiency in a condition where angiotensin II is 
important to maintain GFR, i.e: bilateral stenosis of 
artery renal, severe dehydration, and hyponatremi7.
 RAAS blocking agents are integral modalities for 
treatment of myocardial infarct, hypertension, heart 
failure. Many studies stated that these agents have 
Table 3. Predictors CIN
Predictors OR 95% CI P-value
LVEF ≤ 40% 2,300 1,028 – 5,143 0,043
Duration of PCI was performed 
> 65 minutes
1,955 0,965 – 3,958 0,063
Anemia 2,628 1,274 – 5,422 0,009
CHF 1,567 0,697 – 3,524 0,277
GFR ≤ 60 mL/min 2,782 1,293 – 5,987 0,009
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beneficial effects on reducing the progression of renal 
failure in DM. Nevertheless, a systematic review from 
5 RCTs with 678 patients concluded that there is no 
compelling evidence for stopping or starting ACE 
I before PCI21. The reasons behind this conclusion 
probably due to the heterogeneity of study designs, 
small sample size, the difference in a baseline population, 
prevention procedures, and different definition of CIN 
itself21. In our study, we had younger subjects but with 
worse renal impairment. These pre-existing renal disease 
and medical conditions in both groups also helped to 
explain the result. The other factors were small sample 
size and wide individual variation. Although our finding 
did not answer the hypothesis, if we looked at a different 
view, chronic RAAS blocker usage did not have negative 
effects on younger subjects with renal impairment.
 One thing not to forget is the chemical properties 
of RAAS blocking agents. Each of these agents has 
their own lipid solubilities, plasma protein bindings, 
bioavailabilities, plasma half-lives, and elimination 
properties which determine different onsets, duration 
of actions, and the effectivities of RAAS blockade. One 
to argue, these characteristics would lead to a different 
result on the development of CIN.
Risk Factors of CIN
LVEF ≤ 40% is the main predictor of CIN22. Other 
studies suggested that LVEF ≤ 40%  increased the 
likelihood of developing CIN >7x23. Low LVEF are 
associated with poor hemodynamic and unstable 
perfusion to a target organ. The kidney is the target 
organ that suffers much when these conditions occurred 
since renal blood flow is affected by intrinsic and 
extrinsic factors. One to remember is pathomechanism 
of CIN that develop due to the decrease of renal blood 
flow following contrast administration19.
 GFR ≤ 60 mL/min is also an independent predictor 
for CIN and has an important predictive value24. GFR 
≤ 60 mL/min is clinically important since it’s used as a 
cutoff value to define patients with renal impairment. 
Pre-existing renal impairment also an important risk 
factor for CIN14. Duration of PCI > 65 min also 
included in CIN predictors. Rationally, the longer the 
duration of PCI, the larger the amount of contrast media 
being used, and the longer the toxic effect of contrast 
media are exposed. The accumulation of these factors 
contributes to the development of CIN25,26. State of 
anemia prevalence to be found in patients with DM27. 
Studies stated that this condition was an important 
risk factor for CIN28,29. The outer medullary is prone 
to hypoxic condition due to high metabolic activities 
and low oxygen pressure. Contrast media increase the 
oxygen – hemoglobin affinity, therefore decreasing 
transfer oxygen to peripheral region28,29.
 Our study has some limitations: the new definition 
of CIN was assigned in 2007 to accommodate a mild 
increase of serum creatinin that already had clinical 
implication30. Also in 2011, a new guideline stated 
that every patient prior to PCI need to perform a risk 
assessment and progressive prevention procedures. CIN 
decrease respectively with incidence 7,1% - 9,6%31,32. 
However, we still used the old definition of CIN 
because of lack of data we had. This was a single-center 
study with historical cohort design, thus allowed bias on 
internal validity. On GFR, we still used Cockroft-Gault 
formulation to calculate renal function, although cystatin 
C, N-acetyl-glucosaminidase, and inulin clearance may 
provide a more sensitive estimate renal functions7. The 
heterogeneity duration after PCI to measure creatinine 
serum were also feared to cause inconsistencies in the 
study. However, this is the first study that discusses the 
relationship between chronic used of RAAS blocking 
agents especially in Indonesia and next study with the 
design that accommodates prospective or RCT are 
needed to examine the relationship lack in this study.
Conclusion
In conclusion, the present study state that chronic used 
of RAAS blocking agents do not increase the incidence 
of CIN. LVEF ≤ 40%, GFR ≤ 60 mL/min, and anemia 
are important predictors for CIN. A future study that 
accommodates a lack of finding in this study is needed.
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